Form 8-K   

UNITED STATES  

SECURITIES AND EXCHANGE COMMISSION  

Washington, D.C. 20549  

FORM 8-K  

Current Report  

Pursuant to Section 13 or 15(d)  

of the Securities Exchange Act of 1934  

Date of report (Date of earliest event reported): February 22, 2016  

UNITEDHEALTH GROUP INCORPORATED  

(Exact name of registrant as specified in its charter)  

  [DATA_TABLE_REMOVED] 

  [DATA_TABLE_REMOVED] 

Registrant’s telephone number, including area code: (952) 936-1300  

N/A  

(Former name or former address, if changed since last report.)  

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:  

 ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)  

 ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)  

 ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))  

 ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))  

 Item 8.01. Other Events.  

On February 22, 2016, UnitedHealth Group Incorporated (the “Company”) agreed to sell (i) its 1.700% Notes due February 15, 2019 in the aggregate principal amount of $750,000,000, (ii) its 2.125% Notes due March 15, 2021 in the aggregate principal amount of $750,000,000 and (iii) its 3.100% Notes due March 15, 2026 in the aggregate principal amount of $1,000,000,000 (collectively, the “Notes”), pursuant to the Underwriting Agreement, dated February 22, 2016 (the “Underwriting Agreement”), and the Pricing Agreement, dated February 22, 2016 (the “Pricing Agreement”), both among the Company and Wells Fargo Securities, LLC, Barclays Capital Inc., Goldman, Sachs & Co., Mizuho Securities USA Inc. and U.S. Bancorp Investments, Inc., as representatives of the several underwriters listed on Schedule I to the Pricing Agreement.  

The Notes were issued on February 25, 2016 pursuant to the Indenture, dated as of February 4, 2008, between the Company and U.S. Bank National Association, as trustee (the “Indenture”), and Officers’ Certificates and Company Orders, each dated February 25, 2016, relating to each series of the Notes, in each case, pursuant to Sections 201, 301 and 303 of the Indenture.  

The Notes have been registered under the Securities Act of 1933, as amended, pursuant to the Company’s automatic shelf registration statement on Form S-3, File No. 333-193958 (the “Registration Statement”). The Company is filing this Current Report on Form 8-K to file with the Securities and Exchange Commission certain documents related to the issuance of the Notes that will be incorporated by reference into the Registration Statement as exhibits thereto.  

The Underwriting Agreement is filed herewith as Exhibit 1.1. The Pricing Agreement is filed herewith as Exhibit 1.2. The Officers’ Certificates and Company Orders relating to the Notes, each including the applicable form of Note, are filed herewith as Exhibit 4.1, Exhibit 4.2 and Exhibit 4.3. The legal opinion with respect to the validity of the Notes is filed herewith as Exhibit 5.1.  

 Item 9.01. Financial Statements and Exhibits.  

(d) Exhibits  

  [DATA_TABLE_REMOVED] 

2  

Signatures  

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.  

Date: February 25, 2016  

 [DATA_TABLE_REMOVED] 

3  

EXHIBIT INDEX  

  [DATA_TABLE_REMOVED]